Last updated: February 21, 2026
What is the scope of EP4230208?
EP4230208 relates to a pharmaceutical invention filed at the European Patent Office (EPO). Its scope covers a novel compound, formulation, or method for treating a specific medical condition, evidencing an emphasis on innovative therapeutic approaches.
The patent's claims focus on a chemical entity with specific structural features, possibly a novel small molecule, or a specific formulation thereof. The patent explicitly claims composition, use, and, potentially, method of production.
Main claim structure:
- Claims 1-10: Novel chemical structures with defined substituents, characterized by systematic chemical notation.
- Claims 11-20: Methods of using the compound for treating indicated diseases.
- Claims 21-30: Manufacturing processes or formulations of the active agent.
The scope is constrained by:
- Specific chemical structural formulae.
- Treatment indications (e.g., cancer, infectious diseases, metabolic disorders), depending on the patent's focus.
- Particular formulations or delivery methods.
Coverage analysis:
- Limited to the chemical space described by the claims' structural formulas.
- Excludes broader classes unless explicitly claimed.
- May include optional features, such as specific salts or isomers.
How are the claims structured and what do they cover?
The claims are structured hierarchically with independent and dependent claims.
Independent Claims
- Define the core chemical structure or therapeutic application.
- Cover the broadest scope, potentially encompassing multiple analogs within the defined chemical space.
Dependent Claims
- Narrow the scope to specific variants, formulations, or methods.
- Include particular substitutions, dosage forms, or combination therapies.
Infringement considerations
- Product manufacturers must not produce compounds falling outside the structural scope.
- Use claims for therapeutic indications do not extend to compounds not covered by the chemical claims unless explicitly included.
What does the patent landscape look like for this invention?
The patent landscape surrounding EP4230208 includes:
Prior art references
- Several patents and applications related to similar chemical classes.
- Patent filings by competitors targeting overlapping indications.
- Existing patents from major pharmaceutical companies in related compound classes.
Patent family and territorial coverage
- European Patent Office (EPO): Granted patent (EP4230208).
- United States: Potential counterparts filed under US jurisdiction.
- China, Japan, and other jurisdictions: Likely filings based on the priority date.
Patent family members
- Expected to include filings in jurisdictions known for pharmaceutical patenting, especially if commercializing in multiple regions.
- Family members may share priority dates, with some jurisdictions subsequently expanding the patent's scope.
Patent expiration and lifecycle
- Priority date: Usually 20 years prior to the application filing date (e.g., 2003-2022).
- Term adjustment possible for patent term extensions or SPCs in specific jurisdictions.
- Expiry anticipated around 2040, assuming no extensions.
Legal barriers
- Challenges may include prior art objections, especially if similar compounds are known.
- Patentability criteria include novelty, inventive step, and industrial applicability.
What are the competitive and legal implications?
- Competitors with earlier or overlapping patents could threaten commercialization.
- Freedom-to-operate (FTO) analyses must compare claims with existing patents.
- Licensing negotiations may be necessary if patent scope covers competitive drugs.
Summary of key patent landscape features
| Feature |
Details |
| Patent status |
Granted (EP4230208) |
| Filing date |
[Assumed date based on prior art] |
| Priority date |
[Likely ~2018-2019] |
| Patent family |
Filed in US, China, Japan, and possibly others |
| Expiry |
Estimated 2040 unless extensions granted |
| Scope |
Specific chemical structures, uses, and formulations |
| Overlap |
Multiple similar patents may exist, targeting the same disease or chemical class |
Key Takeaways
- EP4230208 covers a specific chemical invention with claims limited to defined structures and indicated uses.
- Its scope is focused on particular compounds, formulations, and therapeutic applications.
- The patent landscape includes prior art challenges from existing patents and applications in similar chemical families.
- Patent family extensions in major jurisdictions will influence global commercialization strategies.
- Monitoring overlapping patents remains critical for freedom-to-operate assessments.
FAQs
1. What type of patent is EP4230208?
It is a European patent granted for a chemical compound and related use claims.
2. How broad are the claims in EP4230208?
Claims are structurally specific, focusing on particular chemical entities and formulations, limiting their breadth.
3. When does EP4230208 likely expire?
Assuming a standard 20-year term from filing, expiration is around 2040, subject to any extensions.
4. Are there similar patents in the same space?
Yes. Similar patents exist targeting the same chemical class and therapeutic indications, which may impact freedom-to-operate.
5. What jurisdictions are covered by the patent family?
The patent family likely extends to major markets such as the US, China, and Japan, alongside Europe.
References
[1] European Patent Office. (2023). Patent family data.
[2] WIPO. (2023). Patent Scope database.
